Strategies for combining immunotherapy with radiation for anticancer therapy

Immunotherapy

Volumn 7, Issue 9, 2015, Pages 967-980

  Seyedin, Steven N ^a   Schoenhals, Jonathan E ^a   Lee, Dean A ^b   Cortez, Maria A ^a   Wang, Xiaohong ^a   Niknam, Sharareh ^a   Tang, Chad ^a   Hong, David S ^a   Naing, Aung ^a   Sharma, Padmanee ^a   Allison, James P ^a   Chang, Joe Y ^a   Gomez, Daniel R ^a   Heymach, John V ^a   Komaki, Ritsuko U ^a   Cooper, Laurence J ^a   Welsh, James W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

abscopal effect; CAR T cells; immune checkpoints; immunotherapy; ipilimumab; lung cancer; melanoma; nivolumab; OX40; radiation

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GLYCOPROTEIN GP 100 VACCINE; IMIQUIMOD; IMMUNOSTIMULATING AGENT; IPH 2101; IPILIMUMAB; MONOCLONAL ANTIBODY; MPDL 3280A; NIVOLUMAB; OX40 AGONIST; PEMBROLIZUMAB; RITUXIMAB; TICILIMUMAB; UNCLASSIFIED DRUG; VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL ENGINEERING; CELL THERAPY; CHRONIC LEUKEMIA; ESOPHAGUS CANCER; GLIOMA; HUMAN; IMMUNOCOMPROMISED PATIENT; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; METASTATIC MELANOMA; MULTIPLE MYELOMA; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SMALL CELL LUNG CANCER; STEREOTACTIC RADIOSURGERY; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECTS; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METASTASIS; NEOPLASMS; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CTLA-4 ANTIGEN; GENETIC ENGINEERING; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NEOPLASM METASTASIS; NEOPLASMS; RADIOIMMUNOTHERAPY; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84947560428     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.65     Document Type: Review

References (106)

1. Rusthoven KE, Kavanagh BD, Burri SH et al. Multiinstitutional Phase I/II trial of stereotactic body radiation therapy for lung metastases. J. Clin. Oncol. 27(10), 1579-1584 (2009).
2. Rusthoven KE, Kavanagh BD, Cardenes H et al. Multiinstitutional Phase I/II trial of stereotactic body radiation therapy for liver metastases. J. Clin. Oncol. 27(10), 1572-1578 (2009).
3. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: A paradigm shift. J. Natl Cancer Inst. 105(4), 256-265 (2013).
4. Tang C, Wang X, Soh H et al. Combining radiation and immunotherapy: A new systemic therapy for solid tumors? Cancer Immunol. Res. 2(9), 831-838 (2014).
5. Camphausen K, Moses MA, Menard C et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 63(8), 1990-1993 (2003).
6. Chakravarty PK, Guha C, Alfieri A et al. Flt3l therapy following localized tumor irradiation generates longterm protective immune response in metastatic lung cancer: its implication in designing a vaccination strategy. Oncology 70(4), 245-254 (2006).
7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012).
8. Hodi FS, O'Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
9. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013)
10. Anderson AC. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol. Res. 2(5), 393-398 (2014).
11. Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The tnfrs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr. Opin. Immunol. 25(2), 230-237 (2013).
12. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 1(6), 365-372 (2013).
13. Hiniker SM, Chen DS, Reddy S et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl. Oncol. 5(6), 404-407 (2012).
14. Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol. Ther. 8(23), 2211-2220 (2009).
15. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
16. Robert C, Ribas A, Wolchok JD et al. Anti-programmeddeath-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a Phase 1 trial. Lancet 384(9948), 1109-1117 (2014).
17. Powles T, Eder JP, Fine GD et al. Mpdl3280a (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528), 558-562 (2014).
18. Spigel DR, Reckamp KL, Rizvi NA et al. A Phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33, (Suppl.; abstr 8009) (2015).
19. Deng L, Liang H, Burnette B et al. Irradiation and anti-PD-l1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124(2), 687-695 (2014).
20. Zeng J, See AP, Phallen J et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86(2), 343-349 (2013).
21. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-l1 antibody MPDL3280a in cancer patients. Nature 515(7528), 563-567 (2014).
22. Clinicaltrials.gov. https://clinicaltrials.gov/
23. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734-1736 (1996).
24. Demaria S, Kawashima N, Yang AM et al. Immunemediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11(2 Pt 1), 728-734 (2005).
25. Yoshimoto Y, Suzuki Y, Mimura K et al. Radiotherapyinduced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS ONE 9(3), e92572 (2014).
26. Twyman-Saint Victor C, Rech AJ, Maity A et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547), 373-377 (2015).
27. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int. J. Radiat. Oncol. Biol. Phys. 85(2), 293-295 (2013).
28. Slovin SF, Higano CS, Hamid O et al. Ipilimumab alone or in combination with radiotherapy in metastatic castrationresistant prostate cancer: results from an open-label, multicenter Phase I/II study. Ann. Oncol. 24(7), 1813-1821 (2013).
29. Paterson DJ, Jefferies WA, Green JR et al. Antigens of activated rat T lymphocytes including a molecule of 50,000 MR detected only on CD4 positive T blasts. Mol. Immunol. 24(12), 1281-1290 (1987).
30. Hirschhorn-Cymerman D, Budhu S, Kitano S et al. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J. Exp. Med. 209(11), 2113-2126 (2012).
31. Ruby CE, Montler R, Zheng R, Shu S, Weinberg AD. IL-12 is required for anti-OX40-mediated CD4 T cell survival. J. Immunol. 180(4), 2140-2148 (2008).
32. So T, Choi H, Croft M. OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling. J. Immunol. 186(6), 3547-3555 (2011).
33. Yamaki S, Ine S, Kawabe T et al. Ox40 and IL-7 play synergistic roles in the homeostatic proliferation of effector memory CD4(+) T cells. Eur. J. Immunol. 44(10), 3015-3025 (2014).
34. Byun M, Ma CS, Akcay A et al. Inherited human OX40 deficiency underlying classic kaposi sarcoma of childhood. J. Exp. Med. 210(9), 1743-1759 (2013).
35. Baeyens A, Saadoun D, Billiard F et al. Effector T cells boost regulatory T cell expansion by IL-2, TNF, OX40, and plasmacytoid dendritic cells depending on the immune context. J. Immunol. 194(3), 999-1010 (2015).
36. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating fcgammars, leading to antitumor efficacy. Immunol. Cell Biol. 92(6), 475-480 (2014).
37. Mahmud SA, Manlove LS, Schmitz HM et al. Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells. Nat. Immunol. 15(5), 473-481 (2014).
38. Piconese S, Timperi E, Pacella I et al. Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis c virus-infected liver tissue. Hepatology 60(5), 1494-1507 (2014).
39. Redmond WL, Linch SN, Kasiewicz MJ. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol. Res. 2(2), 142-153 (2014).
40. Voo KS, Bover L, Harline ML et al. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J. Immunol. 191(7), 3641-3650 (2013).
41. Voo KS, Foglietta M, Percivalle E et al. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int. J. Cancer 135(12), 2834-2846 (2014).
42. Golovina TN, Mikheeva T, Suhoski MM et al. CD28 costimulation is essential for human T regulatory expansion and function. J. Immunol. 181(4), 2855-2868 (2008).
43. Yokouchi H, Yamazaki K, Chamoto K et al. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. Cancer Sci. 99(2), 361-367 (2008).
44. Gough MJ, Crittenden MR, Sarff M et al. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J. Immunother. 33(8), 798-809 (2010).
45. Curti BD, Kovacsovics-Bankowski M, Morris N et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73(24), 7189-7198 (2013).
46. Magdalena Kovacsovics-Bankowski LC, Vercellini J, Crittenden M, Lary S, Curti B, Weinberg A. Phase i/ii clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis. J. Immunother. Cancer 1, 255 (2013).
47. Tang C, Liao Z, Gomez D et al. Lymphopenia association with gross tumor volume and lung v5 and its effects on nonsmall cell lung cancer patient outcomes. Int. J. Radiat. Oncol. Biol. Phys. 89(5), 1084-1091 (2014).
48. Rosenberg SA. IL-2: The first effective immunotherapy for human cancer. J. Immunol. 192(12), 5451-5458 (2014).
49. Wu R, Forget MA, Chacon J et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J. 18(2), 160-175 (2012).
50. Besser MJ, Shapira-Frommer R, Treves AJ et al. Clinical responses in a Phase II study using adoptive transfer of shortterm cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16(9), 2646-2655 (2010).
51. Filatenkov A, Baker J, Muller AM et al. Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion. Radiat. Res. 182(2), 163-169 (2014).
52. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550-4557 (2011).
53. Gross G, Waks T, Eshhar Z. Expression of immunoglobulint-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86(24), 10024-10028 (1989).
54. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3(95), 95ra73 (2011).
55. Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr. Opin. Immunol. 33C, 9-15 (2015).
56. Guest RD, Hawkins RE, Kirillova N et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scfvs and antigens. J. Immunother. 28(3), 203-211 (2005).
57. Hudecek M, Lupo-Stanghellini MT, Kosasih PL et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ror1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19(12), 3153-3164 (2013).
58. Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IGG1 FC 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther. 17(10), 1206-1213 (2010).
59. Hudecek M, Sommermeyer D, Kosasih PL et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3(2), 125-135 (2015).
60. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116(7), 1035-1044 (2010).
61. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/Akt/Bcl-xL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18(2), 413-420 (2010).
62. Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71(17), 5697-5706 (2011).
63. Pegram HJ, Lee JC, Hayman EG et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119(18), 4133-4141 (2012).
64. Hassan R, Williams-Gould J, Steinberg SM et al. Tumordirected radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts. Clin. Cancer Res. 12(16), 4983-4988 (2006).
65. Cao N, Li S, Wang Z et al. Nf-kappab-mediated HER2 overexpression in radiation-adaptive resistance. Radiat. Res. 171(1), 9-21 (2009).
66. Bhardwaj V, Zhan Y, Cortez MA et al. c-met inhibitor mk-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J. Thorac. Oncol. 7(8), 1211-1217 (2012).
67. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12(4), 239-252 (2012).
68. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cellbased immunotherapy for malignant diseases. Cell Mol. Immunol. 10(3), 230-252 (2013).
69. Sconocchia G, Eppenberger S, Spagnoli GC et al. NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology 3(8), e952197 (2014).
70. Baskic D, Vujanovic L, Arsenijevic N, Whiteside TL, Myers EN, Vujanovic NL. Suppression of natural killer-cell and dendritic-cell apoptotic tumoricidal activity in patients with head and neck cancer. Head Neck 35(3), 388-398 (2013).
71. Piroozmand A, Hassan ZM. Evaluation of natural killer cell activity in pre and post treated breast cancer patients. J. Cancer Res. Ther. 6(4), 478-481 (2010).
72. Iliopoulou EG, Kountourakis P, Karamouzis MV et al. A Phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer. Immunol. Immunother. 59(12), 1781-1789 (2010).
73. Tonn T, Schwabe D, Klingemann HG et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15(12), 1563-1570 (2013).
74. Arai S, Meagher R, Swearingen M et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A Phase I trial. Cytotherapy 10(6), 625-632 (2008).
75. Heo W, Lee YS, Son CH, Yang K, Park YS, Bae J. Radiationinduced matrix metalloproteinases limit natural killer cell-mediated anticancer immunity in NCI-H23 lung cancer cells. Mol. Med. Rep. 11(3), 1800-1806 (2015).
76. Lim SH, Chua W, Cheng C et al. Effect of neoadjuvant chemoradiation on tumor-infiltrating/associated lymphocytes in locally advanced rectal cancers. Anticancer Res. 34(11), 6505-6513 (2014).
77. Lawrence MS, Stojanov P, Polak P et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 499(7457), 214-218 (2013).
78. Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366(10), 925-931 (2012).
79. Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371(23), 2189-2199 (2014).
80. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9(10), 775-789 (2010).
81. Ueno K, Hirata H, Shahryari V et al. Tumour suppressor microRNA-584 directly targets oncogene rock-1 and decreases invasion ability in human clear cell renal cell carcinoma. Br. J. Cancer 104(2), 308-315 (2011).
82. Mishra S, Deng JJ, Gowda PS et al. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor ii (tgfbr2) expression in prostate cancer. Oncogene 33(31), 4097-4106 (2014).
83. Yamashita R, Sato M, Kakumu T et al. Growth inhibitory effects of mir-221 and mir-222 in non-small cell lung cancer cells. Cancer Med. doi:10.1002/cam4.412 (2015) (Epub ahead of print).
84. Skinner HD, Lee JH, Bhutani MS et al. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer 120(23), 3635-3641 (2014).
85. Wang Z, Han J, Cui Y, Fan K, Zhou X. Circulating microRNA-21 as noninvasive predictive biomarker for response in cancer immunotherapy. Med. Hypotheses 81(1), 41-43 (2013).
86. Thorsen SB, Obad S, Jensen NF, Stenvang J, Kauppinen S. The therapeutic potential of microRNAs in cancer. Cancer J. 18(3), 275-284 (2012).
87. Young K, Cottam B, Baird JR, Gough MJ, Crittenden M. Ideal timing of immunotherapy with radiation in murine tumor models. Int. J. Radiat. Oncol. Biol. Phys. 90(1) (Suppl.), S58 (2014).
88. Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol. Cancer Ther. 11(5), 1062-1070 (2012).
89. Belcaid Z, Phallen JA, Zeng J et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS ONE 9(7), e101764 (2014).
90. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting TIM-3 and Pd-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207(10), 2187-2194 (2010).
91. Zhou Q, Munger ME, Veenstra RG et al. Coexpression of TIM-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117(17), 4501-4510 (2011).
92. Gautron AS, Dominguez-Villar M, De Marcken M, Hafler DA. Enhanced suppressor function of TIM-3+ FOXP3+ regulatory T cells. Eur. J. Immunol. 44(9), 2703-2711 (2014).
93. Hou H, Liu W, Wu S et al. Tim-3 negatively mediates natural killer cell function in LPS-induced endotoxic shock. PLoS ONE 9(10), e110585 (2014).
94. Rich AM, Hussaini HM, Parachuru VP, Seymour GJ. Tolllike receptors and cancer, particularly oral squamous cell carcinoma. Front. Immunol. 5, 464 (2014).
95. Dewan MZ, Vanpouille-Box C, Kawashima N et al. Synergy of topical Toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin. Cancer Res. 18(24), 6668-6678 (2012).
96. Romagne F, Andre P, Spee P et al. Preclinical characterization of 1-7f9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 114(13), 2667-2677 (2009).
97. Benson DM Jr, Hofmeister CC, Padmanabhan S et al. A Phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120(22), 4324-4333 (2012).
98. Vey N, Bourhis JH, Boissel N et al. A Phase 1 trial of the anti-inhibitory KIR MAB IPH2101 for AML in complete remission. Blood 120(22), 4317-4323 (2012).
99. Li M, Bolduc AR, Hoda MN et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J. Immunother. Cancer 2, 21 (2014).
100. Peng YP, Zhang JJ, Liang WB et al. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. BMC Cancer 14, 738 (2014).
101. Yu J, Du W, Yan F et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 190(7), 3783-3797 (2013).
102. Wang XF, Wang HS, Wang H et al. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: Focus on macrophage polarization of THP-1 cells. Cell Immunol. 289(1-2), 42-48 (2014).
103. Iversen TZ, Engell-Noerregaard L, Ellebaek E et al. Longlasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin. Cancer Res. 20(1), 221-232 (2014).
104. Boothe DL, Coplowitz S, Greenwood E et al. Transforming growth factor beta-1 (TGF-beta1) is a serum biomarker of radiation induced fibrosis in patients treated with intracavitary accelerated partial breast irradiation: preliminary results of a prospective study. Int. J. Radiat. Oncol. Biol. Phys. 87(5), 1030-1036 (2013).
105. Wu CT, Chen MF, Chen WC, Hsieh CC. The role of IL-6 in the radiation response of prostate cancer. Radiat. Oncol. 8, 159 (2013).
106. Kachikwu EL, Iwamoto KS, Liao YP et al. Radiation enhances regulatory T cell representation. Int. J. Radiat. Oncol. Biol. Phys. 81(4), 1128-1135 (2011).